Načítá se...
A meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancer
BACKGROUND: Patients with metastatic colorectal cancer (mCRC) often suffer from progressive disease despite previous therapy. It has been a great challenge for those patients. In 2012, regorafenib was approved for mCRC. In this meta-analysis, we aimed to collect and present existing data to exploret...
Uloženo v:
| Vydáno v: | Medicine (Baltimore) |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Wolters Kluwer Health
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6200445/ https://ncbi.nlm.nih.gov/pubmed/30290640 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000012635 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|